First‐line drugs inhibiting the renin angiotensin system versus other first‐line antihypertensive drug classes for hypertension Angiotensin Converting Enzyme Inhibit s angiotensin dipeptidyl kininase ii convert enzyme inhibit recept block kf ace inhibit kf acei kf alacepril altiopril ancovenin benazepril captopril ceranapril ceronapril cilazapril deacetylalacepril delapril derapril enalapril enalaprilat epicaptopril fasidotril fosinopril f oxymithine gemopatrilat idapril imidapril indolapril libenzapril lisinopril moexipril moveltipril omapatrilat pentopril perindopril pivopril quinapril ramipril rentiapril saralasin s nitrosocaptopril spirapril temocapril teprotide tr olapril utibapril zabicipril zofenopril Aceon Accupril Altace Capoten Lotensin Mavik Monopril Prinivil Univas Vasotec Zestril kf Angiotensin Recept Antagonists angiotensin recept antagon recept block kf arb arbs kf abitesartan azilsartan c esartan elisartan embusartan eprosartan f asartan irbesartan KT losartan milfasartan olmesartan saprisartan tasosartan telmisartan valsartan zolasartan kf renin ai aliskiren ciprokiren ditekiren enalkiren remikiren rasilez tekturna terlakiren zankiren RAS renin inhibit kf calcium channel blockers amlodipine aranidipine barnidipine bencyclane benidipine bepridil cilnidipine cinnarizine clentiazem darodipine diltiazem efonidipine elgodipine etafenone fantofarone felodipine fendiline flunarizine gallopamil isradipine lacidipine lercanidipine lidoflazine lomerizine manidipine mibefradil nicardipine nifedipine niguldipine nilvadipine nimodipine nisoldipine nitrendipine perhexiline prenylamine semotiadil terodiline tiapamil verapamil Cardizem CD Dilac XR Tiazac Cardizem Calan Isoptin Calan SR Isoptin SR Coer Covera HS Verelan PM kf calcium antagonist block inhibit kf methyldopa alphamethyldopa amodopa dopamet dopegyt dopegit dopegite emdopa hyperpax hyperpaxa methylpropionic acid dopergit meldopa methyldopate medopa medomet sembrina aldomet aldometil aldomin hydopa methyldihydroxyphenylalanine methyl dopa mulfasin presinol presolisin sedometil sembrina taquinil dihydroxyphenylalanine methylphenylalanine methylalanine alpha methyl dopa reserpine serpentina rauwolfia serpasil clonidine adesipress arkamin caprysin catapres catasan chlofazolin chlophazolin clinidine clofelin clofenil clomidine clondine clonistada clonnirit clophelin dichl ophenylaminoimidazoline dixarit duraclon gemiton haemiton hemiton imidazoline isoglaucon klofelin klofenil m t n mopresan paracefan st st tesno timelets hydralazine dihydralazine hydralazin hydrallazin hydralizine hydrazinophtalazine hydrazinophthalazine hydrazinophtalizine dralzine hydralacin hydrolazine hypophthalin hypoftalin hydrazinophthalazine idralazina hydrazinophthalazine apressin nepresol apressoline apresoline apresolin alphapress alazine idralazina lopress pleth it praeparat kf adrenergic beta antagonists acebutolol adimolol afurolol alprenolol amosulalol arotinolol atenolol befunolol betaxolol bevantolol bisoprolol bopindolol b naprolol brefonalol bucindolol bucumolol bufetolol bufuralol bunitrolol bunolol bupranolol butofilolol butoxamine carazolol carteolol carvedilol celiprolol cetamolol chl talidone cl anolol cyanoiodopindolol cyanopindolol deacetylmetipranolol diacetolol dihydroalprenolol dilevalol epanolol esmolol exaprolol falintolol flestolol flusoxolol hydroxybenzylpinodolol hydroxycarteolol hydroxymetoprolol indenolol iodocyanopindolol iodopindolol iprocrolol isoxaprolol labetalol l iolol levobunolol levomoprolol medroxalol mepindolol methylthiopropranolol metipranolol metoprolol moprolol nadolol oxprenolol penbutolol pindolol nadolol nebivolol nifenalol nipradilol oxprenolol pafenolol pamatolol penbutolol pindolol practolol primidolol prizidilol procinolol pronetalol propranolol proxodolol ridazolol salcardolol soquinolol sotalol spirendolol talinolol tertatolol tienoxolol tilisolol timolol tolamolol toliprolol tribendilol xibenolol kf beta adrenergic antagonist block recept kf adrenergic alpha antagonists alfuzosin bunazosin doxazosin metazosin neldazosin prazosin silodosin tamsulosin terazosin tiodazosin trimazosin kf adrenergic alpha antagonist kf adrenergic alpha recept block kf thiazides sodium potassium chl ide sy ter inhibit s loop ceiling diuretic kf amil ide benzothiadiazine bendroflumethiazide bumetanide chl othiazide cyclopenthiazide furosemide hydrochl othiazide hydroflumethiazide methyclothiazide metolazone polythiazide trichl methiazide veratide thiazide kf chl thalidone chl talidone phthalamudine chl phthalidolone oxodoline thalitone hygroton indapamide metindamide kf hypertension hypertens kf high elevat rais blood pressure kf r omized controlled trial controlled clinical trial r omized placebo drug therapy r omly trial groups animals humans animals Pregnancy Hypertension Pregnancy Induced Pregnancy Co lications Cardiovascular Ocular Hypertension pregnancy induced ocular hypertens preecla sia pre ecla sia limit to ed Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide.Diuretics are recommended as first-line agents for the treatment of hypertension. This randomized, double-blind, multicenter study assessed the long-term efficacy and safety of the direct renin inhibitor aliskiren in comparison with the diuretic hydrochlorothiazide in patients with essential hypertension.After a 2- to 4-week placebo run-in, 1124 patients (mean sitting diastolic blood pressure [BP] 95 to 109 mm Hg) were randomized to aliskiren 150 mg (n=459), hydrochlorothiazide 12.5 mg (n=444), or placebo (n=221) once daily. Forced titration (to aliskiren 300 mg or hydrochlorothiazide 25 mg) occurred at week 3; at week 6, patients receiving placebo were reassigned (1:1 ratio) to aliskiren 300 mg or hydrochlorothiazide 25 mg. From week 12, amlodipine 5 mg was added and titrated to 10 mg from week 18 for patients whose BP remained uncontrolled. Efficacy variables were analyzed for the intent-to-treat population with the use of the last observation carried forward method. BP reductions (mean sitting systolic BP/mean sitting diastolic BP) were significantly greater with aliskiren- versus hydrochlorothiazide-based treatment at week 26 (-20.3/-14.2 versus -18.6/-13.0 mm Hg; P<0.05) and were also greater at week 52 (-22.1/-16.0 versus -21.2/-15.0 mm Hg; P<0.05 for mean sitting diastolic BP). At the end of the monotherapy period (week 12), aliskiren 300 mg was superior to hydrochlorothiazide 25 mg in reducing BP (-17.4/-12.2 versus -14.7/-10.3 mm H; P<0.001). Adverse event rates were similar with aliskiren- (65.2%) and hydrochlorothiazide-based therapy (61.5%). Hypokalemia was more frequent with hydrochlorothiazide-based therapy than aliskiren-based therapy (17.9% versus 0.9%; P<0.0001).Aliskiren treatment, both as monotherapy and with optional addition of amlodipine, provided significantly greater BP reductions than the respective hydrochlorothiazide regimens. Aliskiren-based therapy was well tolerated. Direct renin inhibition with aliskiren therefore represents an effective option for the long-term treatment of essential hypertension.